EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol

Kadri Tamme, Stefan Acosta, Alan Biloslavo, Martin Björck, Dumitru Casian, Dimitrios Damaskos, Alastair Forbes, Karri Kase, Kalle Kisand, Ines Lakbar, Vladislav Mihnovitš, Marko Murruste und 6 weitere

BMC Surgery · 2024

DOI: 10.1186/s12893-024-02491-3 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift BMC Surgery, 2024. Verfasst von Kadri Tamme und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Tartu, Tartu, Estonia. kadri.tamme@kliinikum.ee. Hauptthemen laut MEDLINE: Biomarkers, Mesenteric Ischemia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eesti Teadusagentuur.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute mesenteric ischaemia (AMI) is a life-threatening disease where early diagnosis is critical to avoid morbidity and mortality from extensive irreversible bowel necrosis. Appropriate prediction of presence of bowel necrosis is currently not available but would help to choose the optimal method of treatment. The study aims to identify combinations of biomarkers that can reliably identify AMI and distinguish between potentially reversible and irreversible bowel ischaemia.

Methods

This is a prospective multicentre study. Adult patients with clinical suspicion of AMI ( n = 250) will be included. Blood will be sampled on admission, at and after interventions, or during the first 48 h of suspicion of AMI if no intervention undertaken. Samples will be collected and the following serum or plasma biomarkers measured at Tartu University Hospital laboratory: intestinal fatty acid-binding protein (I-FABP), alpha-glutathione S-transferase (Alpha- GST), interleukin 6 (IL-6), procalcitonin (PCT), ischaemia-modified albumin (IMA), D-lactate, D-dimer, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) and lipopolysaccharide-binding protein (LBP). Additionally, more common laboratory markers will be measured in routine clinical practice at study sites. Diagnosis of AMI will be confirmed by computed tomography angiography, surgery, endoscopy or autopsy. Student’s t or Wilcoxon rank tests will be used for comparisons between transmural vs. suspected (but not confirmed) AMI (comparison A), confirmed AMI of any stage vs suspected AMI (comparison B) and non-transmural AMI vs transmural AMI (comparison C). Optimal cut-off values for each comparison will be identified based on the AUROC analysis and likelihood ratios calculated. Positive likelihood ratio > 10 (> 5) and negative likelihood ratio < 0.1 (< 0.2) indicate high (moderate) diagnostic accuracy, respectively. All biomarkers with at least moderate accuracy will be entered as binary covariates (using the best cutoffs) into the multivariable stepwise regression analysis to identify the best combination of biomarkers for all comparisons separately. The best models for each comparison will be used to construct a practical score to distinguish between no AMI, non-transmural AMI and transmural AMI.

Discussion

As a result of this study, we aim to propose a score including set of biomarkers that can be used for diagnosis and decision-making in patients with suspected AMI.

Trial registration

NCT06212921 (Registration Date 19–01-2024).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersMesenteric IschemiaAdultHumansAcute DiseasePredictive Value of TestsProspective StudiesMulticenter Studies as Topic

Stichwörter der Autor:innen

Acute mesenteric ischaemiaBiomarkersDiagnosis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Institute of Clinical Medicine, University of Tartu, Tartu, Estonia. kadri.tamme@kliinikum.ee.
  • Tartu University Hospital, Tartu, Estonia. kadri.tamme@kliinikum.ee.
  • Department of Clinical Sciences, Lund University, Malmö, Sweden.
  • General Surgery Department, Cattinara University Hospital, Trieste, Italy.
  • Department of Surgical Sciences, Vascular Surgery, Uppsala University, Uppsala, Sweden.
  • Department of General Surgery Nr. 3, "Nicolae Testemitanu" State University of Medicine and Pharmacy, Chisinau, Moldova.

Förderung

  • Eesti Teadusagentuur

Zitieren

APA

Tamme, K., Acosta, S., Biloslavo, A., Björck, M., Casian, D., Damaskos, D., Forbes, A., Kase, K., Kisand, K., Lakbar, I., Mihnovitš, V., Murruste, M., Mändul, M., Nuzzo, A., Padar, M., Starkopf, J., Visconti, D., & Reintam Blaser, A. (2024). Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol. BMC Surgery. https://doi.org/10.1186/s12893-024-02491-3

Vancouver

Tamme K, Acosta S, Biloslavo A, Björck M, Casian D, Damaskos D, et al. Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol. BMC Surgery. 2024. doi:10.1186/s12893-024-02491-3

BibTeX
@article{Tamme2024,
  author = {Tamme, Kadri and Acosta, Stefan and Biloslavo, Alan and Björck, Martin and Casian, Dumitru and Damaskos, Dimitrios and Forbes, Alastair and Kase, Karri and Kisand, Kalle and Lakbar, Ines and Mihnovitš, Vladislav and Murruste, Marko and Mändul, Merli and Nuzzo, Alexandre and Padar, Martin and Starkopf, Joel and Visconti, Diego and Reintam Blaser, Annika},
  title = {Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol},
  journal = {BMC Surgery},
  year = {2024},
  doi = {10.1186/s12893-024-02491-3}
}
Kostenlos starten →